title: An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder.
abstract: BACKGROUND
  The adverse effect profiles of typical and atypical antipsychotics are problematic because of their extrapyramidal and endocrine adverse effects, respectively.
  
  
  METHODS
  Ten adolescent male patients diagnosed with conduct disorder received aripiprazole in doses of ≤20 mg/d in an open-label, intent-to-treat design to establish and characterize the efficacy of the drug in reducing aggressive behavior.
  
  
  RESULTS
  Based on clinician and parent observations, aripiprazole was effective in reducing aggressive behavior in adolescent boys. The change in clinician-observed aggression ratings appears to have been driven by a decrease in physical aggression, whereas the change in parent-observed aggression ratings appears to have been driven by a decrease in verbal aggression and aggression against objects and animals.
  
  
  CONCLUSIONS
  Aripiprazole was an effective and relatively well-tolerated treatment for overall aggression in adolescent males with conduct disorder, in the view of both clinicians and parents. Depending on the observer, aripiprazole improved aggression categorized as physical aggression, verbal aggression, and aggression against objects and animals.
authors.affiliation: Division of Child Psychiatry, University of Iowa, Carver College of Medicine, Iowa City, USA.
authors.forename: Samuel
authors.initials: S
authors.lastname: Kuperman
authors.forename: Chadi
authors.initials: C
authors.lastname: Calarge
authors.forename: Anne
authors.initials: A
authors.lastname: Kolar
authors.forename: Timothy
authors.initials: T
authors.lastname: Holman
authors.forename: Mitchell
authors.initials: M
authors.lastname: Barnett
authors.forename: Paul
authors.initials: P
authors.lastname: Perry
mesh_terms: D000293:Adolescent; D000374:Aggression / Q000187:drug effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D019955:Conduct Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008297:Male; D010865:Pilot Projects; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole